Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AstraZeneca plc (AZN) vs Kraft Heinz Co (KHC) Price & Performance

AstraZeneca plcTrade
Kraft Heinz CoTrade

Price performance (Past 24H)

Key statistics

AstraZeneca plc vs Kraft Heinz Co — how do they compare? AstraZeneca plc trades at $158.58 (market cap $248.14B), while Kraft Heinz Co trades at $24.53 (market cap $29.23B). The key difference: AstraZeneca plc is far larger — about 8.5× Kraft Heinz Co's market cap, and Kraft Heinz Co pays the higher dividend (6.49%). Which is the better fit depends on your goals.

AZNKHC
Market Cap
$248.14B$29.23B
Sector
HealthConsumer Staples
52-Week High
$209.48$28.06
52-Week Low
$147.06$21.21
Enterprise Value
$275.41B$45.55B
Dividend Yield
2.01%6.49%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AstraZeneca plc

AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.

The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.

Kraft Heinz Co

Kraft Heinz (KHC) trades at $24.36, down 2.29% today, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates, but net income margin is negative at -13.64%. The company maintains a $0.40 quarterly dividend, while analyst consensus is mostly Hold. Cash flow from operations improved to $4.46B in 2025, though revenue declined to $24.94B.

Outlook remains cautious due to profit declines and competitive pressures, offset by a low P/E of 13.04 and strategic investments. Key risks include earnings sustainability and high debt. The stock presents value potential but requires monitoring of turnaround execution under CEO Cahillane's strategy.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN

About Kraft Heinz Co

In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.

Read more on KHC